← Lakewood-Amedex Biotherapeutics (LABT)

Lakewood-Amedex Biotherapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 10-QNov. 16, 2026, 5 p.m. ETView on SEC.gov
  • 8-KNov. 16, 2026, 4:35 p.m. ETView on SEC.govOur explainer

    Delisting notice / failure to meet listing standard · Financial statements and exhibits

    AI summary, unreviewedLakewood-Amedex Biotherapeutics receives Nasdaq delisting notice after bid price fell below $1.00 for 30 days and prior reverse split bars compliance period

  • 8-KNov. 10, 2026, 5:20 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedLakewood-Amedex Biotherapeutics (LABT) redeems all 127,097 Series C preferred shares for $1.27 million in cash, eliminating conversion dilution

  • 8-KSept. 28, 2026, 5:49 p.m. ETView on SEC.gov

    Submission of matters to a vote of security holders

  • S-1Sept. 18, 2026View on SEC.gov
  • 10-QAug. 13, 2026, 9:36 p.m. ETView on SEC.gov
  • SCHEDULE 13GAug. 14, 2026, 4:15 p.m. ETView on SEC.gov
  • SCHEDULE 13GAug. 6, 2026, 2:18 p.m. ETView on SEC.gov